Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial

Context Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease. Objective To test for the first time the hypothesis that treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker (ARB) valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine. Design Pre-specified analysis in the VALUE trial. Follow-up averaged 4.2 years. The risk of developing new diabetes was calculated as an odds ratio (OR) with 95% confidence intervals (CI) for different definitions of diabetes. Patients A sample of 9995 high-risk, non-diabetic hypertensive patients. Interventions Valsartan or amlodipine with or without add-on medication [hydrochlorothiazide (HCTZ) and other add-ons, excluding other ARBs, angiotensin-converting enzyme (ACE) inhibitors, CCAs]. Main outcome measure New diabetes defined as an adverse event, new blood-glucose-lowering drugs and/or fasting glucose > 7.0 mmol/l. Results New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (OR 0.77, 95% CI 0.69–0.87, P < 0.0001). Using stricter criteria (without adverse event reports) new diabetes was detected in 495 (9.8%) patients on valsartan and in 586 (11.8%) on amlodipine (OR 0.82, 95% CI 0.72–0.93, P = 0.0015). Conclusion Compared with amlodipine, valsartan reduces the risk of developing diabetes mellitus in high-risk hypertensive patients.

[1]  B. Williams,et al.  The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension , 2005, Journal of hypertension.

[2]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[3]  L. Rydén,et al.  Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. , 2004, European heart journal.

[4]  R. Schall,et al.  Old antihypertensives and new diabetes , 2004, Journal of hypertension.

[5]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[6]  J. Laragh,et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial , 2004, The Lancet.

[7]  G. Reboldi,et al.  Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.

[8]  J. Gayet.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. , 2003, Journal of hypertension.

[9]  J. Laragh,et al.  VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk , 2003 .

[10]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[11]  L. Lind,et al.  Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study , 2003, BMJ : British Medical Journal.

[12]  L. Eberly,et al.  Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. , 2003, Diabetes care.

[13]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[14]  Arya M. Sharma,et al.  Angiotensin blockade prevents type 2 diabetes by formation of fat cells. , 2002, Hypertension.

[15]  L. Kuller,et al.  Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. , 2002, Circulation.

[16]  C. Lamendola,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. , 2002, Circulation.

[17]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[18]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[19]  J. Shaw,et al.  Global and societal implications of the diabetes epidemic , 2001, Nature.

[20]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[21]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[22]  J. Laragh,et al.  Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial , 2001 .

[23]  D. Vidt,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone , 2000 .

[24]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[25]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[26]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[27]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[28]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[29]  G Dunn,et al.  Rationale and design. PRiSM Psychosis Study I. , 1998, The British journal of psychiatry : the journal of mental science.

[30]  S. Julius,et al.  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. , 1998, Blood pressure.

[31]  S. Julius,et al.  The hemodynamic link between insulin resistance and hypertension. , 1991, Journal of hypertension.

[32]  P. Wilson,et al.  The epidemiology of impaired glucose tolerance and hypertension. , 1991, American heart journal.

[33]  H. Lithell.  Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism , 1991, Diabetes Care.

[34]  S. Fajans,et al.  Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. , 1966, The Journal of clinical investigation.

[35]  J. Conn.  Hypertension, the potassium ion and impaired carbohydrate tolerance. , 1965, The New England journal of medicine.

[36]  Alan C. Wilson,et al.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. , 2005, The American journal of cardiology.

[37]  J. Laragh,et al.  The VALUE Trial , 2005 .

[38]  C. Berne,et al.  Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats , 1998, Diabetologia.

[39]  D. Andersen,et al.  Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. , 1983, Diabetes.